skip to the content

Avastin in combination with other standard anticancer agents and treatment modalities

Avastin significantly increased efficacy in combination with immunotherapy in the AVOREN RCC study

Avastin significantly increased efficacy in combination with immunotherapy in the AVOREN RCC study10

Reprinted from The Lancet, 370, Escudier B, et al., 2103–11, Copyright 2007, with permission from Elsevier

  • The ability to apply direct and continuous VEGF inhibition with Avastin in combination with other treatment modalities may increase the available therapeutic options in a number of tumour types.
 
  • In addition to chemotherapy, other types of systemic therapy used in the treatment of cancer include
    • immunotherapy
    • endocrine therapy
    • targeted agents (those acting via recognition of a specific tumour cell marker, e.g. trastuzumab for HER–2).
 
  • Immunotherapy is commonly used in the treatment of RCC
    • in a phase III trial, Avastin significantly increased PFS (p<0.0001) and ORR (p<0.0001) in combination with IFN-α compared with IFN-α plus placebo (figure).10
 
  • Endocrine therapies, such as aromatase inhibitors, and the targeted agent trastuzumab are each used to treat specific subgroups of patients with mBC
    • ongoing phase III studies are investigating Avastin in combination with these treatment modalities.